Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catumaxomab and Chemotherapy in Recurrent Ovarian Cancer
NCT01815528Phase 2Completed
- Start
- Mar 2013
- Primary completion
- Feb 2014
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of catumaxomab in Epithelial Ovarian Cancer (EOC), peritoneal carcinomatosis (PC), fallopian tube cancer (PFTC). Started Mar 2013; status: completed.
02
Drugs
catumaxomab
03
Conditions
Epithelial Ovarian Cancer (EOC)peritoneal carcinomatosis (PC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT01815528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01815528.